Successful Completion of Phase 1 Clinical Trial, Close of Initial Equity Round of Funding, and Addition of Dr. Stanley Marks and John Friedman to Board of Directors Positions CytoAgents for Larger Series A and Phase II Trials. Read more >>
Cardinal O’Hara High School technology specialist Ed Allen is pictured at the school last week. Allen, who is legally…
read moreeSight has announced that its newest vision enhancement technology, eSight 4, is now available in the UK through VisionAid…
read moreIt’s helping the blind to see. A couple in the northern valley was worried that it was an out-of-country…
read moreEmovi, Inc., a medical device company developing products for knee joint assessment, today announced that Eule Glenn has joined…
read moreIn space, no one can steal your data.
Well, that’s the theory, anyway — one that the Boston data storage…
Emovi, Inc. signed a multiyear endorsement agreement with Kansas City Chiefs guard Laurent Duvernay-Tardif, MDCM to help support knowledge…
read moreeSight Corporation, a leading vision enhancing platform, is pleased to announce the appointment of Robert Vaters as President and…
read moreMyomo announced today that it launched its MyoCare program for providing support to first-year users of its MyoPro powered…
read morePlateletBio, a preclinical-stage biotechnology company pioneering an entirely new platform of allogeneic cell therapies based on platelet biology, today…
read moreCorbus Pharmaceuticals Holdings, Inc. (CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious…
read more